REG - Poolbeg Pharma PLC - Directorate Change

Poolbeg PharmaAnnouncement

30/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231130:nRSd1292Va&default-theme=true

RNS Number : 1292V  Poolbeg Pharma PLC  30 November 2023

Poolbeg Pharma plc

Directorate Change

30 November 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM:
POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company
focussed on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, announces a change to its
Board of Directors.

Patrick Ashe, Independent Non-Executive Director, will step down from the
Board at the end of November. Patrick played a significant role in guiding the
Company through its initial phase of development. Eddie Gibson, Non-Executive
Director will replace Patrick as Chair of the Audit & Risk Committee and
Prof Brendan Buckley, Non-Executive Director will become Chair of the
Remuneration Committee.

Cathal Friel, Chairman of Poolbeg Pharma, commented: "We would like to thank
Patrick for his contribution since joining at the IPO, where his knowledge and
experience of growing biopharma companies has been of considerable value.
Patrick joined the Company as part of its IPO and steps down from the Board at
a time when Poolbeg is on an upward trajectory with a robust pipeline of high
value programmes, and at a particularly exciting juncture following the recent
appointment of three key former Amryt Pharma plc leadership members to the
Poolbeg team with the view to replicating the success they had with Amryt.
With a strong financial position, excellent clinical results achieved and
productive partnering discussions ongoing, the Company is well positioned to
generate significant shareholder value."

- Ends -

Enquiries

 Poolbeg Pharma Plc                                                      +44 (0) 207 183 1499
 Jeremy Skillington, CEO

Ian O'Connell, CFO
 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)        +44 (0) 207 220 0500
 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)
 Singer Capital Markets (Joint Broker)                                    +44 (0) 207 496 3000
 Phil Davies, Sam Butcher
 J&E Davy (Joint Broker)                                                 +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist
 Optimum Strategic Communications                                        +44 (0) 208 078 4357
 Nick Bastin,  Vici Rabbetts, Elena Bates

                                                                       poolbeg@optimumcomms.com

About Poolbeg Pharma

Poolbeg Pharma plc is committed to the development and commercialisation of
innovative medicines targeting diseases with a high unmet medical need. Its
model focusses upon developing its exciting clinical assets and
commercialising approved and marketed drugs to fund the development of its
robust pipeline of innovative products, thereby driving significant value
creation.

Poolbeg is led by an experienced leadership team with a history of delivering
significant shareholder value. The team has been strengthened by the
appointment of three former members of the Amryt Pharma plc leadership team,
with the intention of repeating Amryt's success and generating near term
revenues.

Poolbeg's clinical programmes target large addressable markets across cancer
immunotherapies, severe influenza, and metabolic conditions such as obesity
with the development of an oral GLP-1R agonist. It uses a cost-effective
development philosophy to generate high quality human data to support
partnering and further development. Its AI-led programmes analyse unique data
from human challenge trials to identify clinically relevant drug targets and
treatments, leading to faster development and greater commercial appeal.

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABIBDBIBDDGXC